文献速递骨软组织肉瘤与黑色素瘤

晚期或转移性黑色素瘤免疫治疗患者报告结局的预后价值:CheckMate-067研究结果

Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study.
PubMed 文献 · Eur J Cancer · 2024-10-28

基于CheckMate-067研究7.5年随访数据,汇总纳武利尤单抗或纳武利尤单抗联合伊匹木单抗对比伊匹木单抗各治疗组患者报告结局,分析基线及治疗后变化与生存结局的关联。结果显示多数患者报告结局领域,尤其身体功能、总体健康状况/生活质量、疲乏和EQ-5D视觉模拟量表,可预测无进展生存、总生存和黑色素瘤特异性生存;治疗开始后12周达到有意义的改善或维持基线评分者生存结局优于有意义恶化者。

要点

  • 基线及治疗后多数患者报告结局领域可预测无进展生存、总生存和黑色素瘤特异性生存。
  • 身体功能、总体健康状况/生活质量、疲乏和EQ-5D视觉模拟量表的预后价值最突出。
  • 治疗开始后12周患者报告结局达到有意义改善或维持基线评分者,生存结局优于有意义恶化者。

核心结论

  • 基线和治疗期间的患者报告结局,尤其身体功能、总体健康状况/生活质量、疲乏和EQ-5D视觉模拟量表,可预测生存结局。
  • 该知识可能加速开发预后工具,以管理接受免疫治疗的既往未治疗不可切除或转移性黑色素瘤患者。

研究设计与样本

  • 研究使用CheckMate-067的7.5年随访数据,该研究为3期随机双盲研究,比较纳武利尤单抗或纳武利尤单抗联合伊匹木单抗与伊匹木单抗。
  • 患者报告结局采用欧洲癌症研究与治疗组织核心30量表和EQ-5D-3L评估,在基线和治疗开始后后续访视时收集,并跨治疗组汇总。
  • 采用Cox比例风险模型分析基线患者报告结局或较基线变化评分与无进展生存或总生存的关联,采用病因特异性风险模型分析其与黑色素瘤特异性生存的关联。

主要发现

  • 大多数患者报告结局领域的基线评分和较基线变化评分可预测所有生存结局,尤其身体功能、总体健康状况/生活质量、疲乏和EQ-5D视觉模拟量表。
  • 治疗开始后12周达到有意义的改善或维持基线患者报告结局评分者,生存结局优于较基线有意义恶化者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patient-reported outcomes (PROs) that predict survival in cancer patients have yet to be realized as practical tools for clinicians to make better treatment decisions. To identify such PROs in adults with advanced melanoma treated with immunotherapy, this study used 7.5-year follow-up data from CheckMate-067, a phase 3, randomized, double-blind study of nivolumab or nivolumab plus ipilimumab versus ipilimumab. METHODS: PRO data assessed using the European Organization of Research for the Treatment of Cancer Core-30 and EQ-5D-3L at baseline and during subsequent visits after treatment initiation were pooled across treatment arms. Associations between baseline PRO or change from baseline (CFB) scores with survival outcomes (progression-free survival [PFS], overall survival [OS], and melanoma-specific survival [MSS]) were examined using Cox proportional hazards models for PFS or OS and cause-specific hazard models for MSS. RESULTS: Baseline and CFB scores for most PRO domains, especially for physical functioning, global health status/quality of life (GHS/QoL), fatigue, and EQ-5D visual analog scale (VAS), were prognostic of all survival outcomes. Achieving meaningful improvement/maintenance of baseline PRO scores at 12 weeks following treatment initiation predicted better survival outcomes than with meaningful worsening from baseline. CONCLUSIONS: PROs at baseline and during treatment, particularly for physical functioning, GHS/QoL, fatigue, and EQ-VAS, were prognostic of survival outcomes. This knowledge may accelerate development of prognostic tools to manage treatment in patients with previously untreated unresectable or metastatic melanoma who undergo immunotherapy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schadendorf D, Lord-Bessen J, Ejzykowicz F, et al. Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study. Eur J Cancer. 2024. PMID: 39520835. doi:10.1016/j.ejca.2024.115099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。